FDA approved Eli Lilly’s Kisunla for mild and early Alzheimer’s stages, offering a new option to slow cognitive decline by up to eight months through regular IV infusions, despite concerns over study methods. The drug targets amyloid plaque buildup, akin to last year’s approved treatment Leqembi, heralding hope among physicians for managing the incurable disease affecting over eight million Americans, with Medicare expected to cover costs for eligible patients.

FDA approves a second Alzheimer’s drug that can modestly slow disease (AP)

FDA approved Eli Lilly’s Alzheimer’s drug Kinsula (NBC)